High-polymer component of yeast RNA is a specific stimulator of biosynthesis of protein in hematopoietic and immunocompetent organs. Application of the medication increases hemoglobin level in blood and protects animals from stress. It also enhances immunomodulating and antiradiation effect. RNA substance is made of natural materials with use of environmently friendly, safe and nonwaste technology, since the production waste is a yeast protein - in a dry form, a multipurpose fodder component. To produce the medication, readily available and inexpensive natural compounds are used. The equipment used in production lines is much cheaper than similar equipment available at the market. The medication is purer and of higher quality than commercially available analogs. Production costs are lower. There is a high demand for RNA based medications due to growing hematological and immune diseases.

Innovative Aspects:
Innovations:
1) Purity. Compared with other medications based on high-polymer RNA, the developed product does not contain riboproteoglican that strongly impacts biological activity of RNA and can be an allergen.
2) The medication has 1.5 time higher molecular mass than similar products. High molecular mass is a critical parameter related to antiviral properties of RNA.
3) The production technology does not involve application of artificial reagents.

Advantages:
The substance is easy to produce. It is based on available raw materials. THe technology is energy saving, because the production line consists of low-velocity centrifuges. The medication has a high biological activity. It has a wide range of applications: fishery, cattle breeding, aviculture.
It is possible to expand the application range. As a medical drug, the preparation seems perspective for treatment of immunodeficiency states of 3rd degree, leucopenia. It has a immunomodulating effect. It is confirmed from the safety standpoint that RNA relates to a class of practically non-toxic substances, it is not allergenic. It is not accumulated in a living body. It does not have any side effects.
Side product of the production line low-polymer RNA - can be commercially used as a source to make natural "library" of siRNA (small interfering RNA) and as precursors of ribonucleozidmono-, di- and tri-phosphates needed by researchers as well as a raw material in production of a number of drugs with an ability to correct metabolic exchange.

 

Patents/Rights: Patent(s) applied for but not yet granted

Type of Organisation: